Press Release Archive

March 4, 2010 - ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement Surgery

(BUSINESS WIRE)--PRINCETON, N.J.

March 3, 2010 - “Project Runway’s” Tim Gunn Returns to Address Psoriasis™ and Empower Patients to be Confident in Their Personal Style

(BUSINESS WIRE)--Amgen and Pfizer have once again partnered with Tim Gunn, television host, fashion consultant and chief creative officer of Liz Claiborne, Inc., to launch the second year of Addressing Psoriasis™, the disease awareness program designed to help people with psoriasis get more information about their condition and feel more confident in their everyday style. Dermatologist Susan C. Taylor, M.D., and Gunn are working

March 2, 2010 - Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer’s Disease Clinical Development Program

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function. “The

March 1, 2010 - Pfizer Invites Public To View And Listen To Webcast Of Investor Breakfast At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with members of Pfizer’s leadership team at an investor breakfast at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010 at 7:00 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Investor Breakfast at

February 25, 2010 - William Ringo, Pfizer’s Senior Vice President, Worldwide Business Development, Strategy And Innovation, To Retire

(BUSINESS WIRE)--Pfizer Inc. today announced that William Ringo will retire from the company. Mr. Ringo made many important contributions to advance the company’s innovative business development activities. “Bill has accomplished a great deal in positioning Pfizer for future success,” said Jeff Kindler, chairman and chief executive officer, Pfizer. “He has helped diversify Pfizer’s portfolio through our

February 24, 2010 - CDC’s Advisory Committee On Immunization Practices Recommends Pfizer’s Prevnar 13™ Vaccine For The Prevention Of Invasive Pneumococcal Disease In Infants And Young Children In The U.S.

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the United States Centers for Disease Control and Prevention's (CDC’s) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for healthy children aged 2 months through 59 months for the prevention of invasive pneumococcal disease caused by the 13 pneumococcal

February 24, 2010 - Pfizer Receives FDA Approval for Prevnar 13™ for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine. Prevnar 13 is indicated for active immunization of children 6 weeks through 5 years of age for the prevention of invasive disease caused by 13

February 23, 2010 - Lilly, Merck, And Pfizer Join Forces To Accelerate Research And Improve Treatment Of Lung And Gastric Cancers In Asia

(BUSINESS WIRE)--Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.

February 7, 2010 - Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness

(BUSINESS WIRE)--Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage

February 4, 2010 - QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed

February 2, 2010 - Pfizer Reports Fourth-Quarter and Full-Year 2009 Results; Provides 2010 Financial Guidance and 2012 Financial Targets

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts)

January 27, 2010 - New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas

(BUSINESS WIRE)--Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development. “This pipeline of

January 21, 2010 - Data Show Progression-Free Survival Advantage With Sutent® In Patients With Pancreatic Neuroendocrine Tumors

(BUSINESS WIRE)--Pfizer Inc. today announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas. Sunitinib more than doubled the time patients with pancreatic neuroendocrine tumors lived without disease progression compared with patients treated with placebo, according to study

January 20, 2010 - Pfizer and Auxilium Announce Commencement of European Regulatory Review of XIAFLEXTM for the Treatment of Dupuytren’s Contracture

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers

January 6, 2010 - Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma

(BUSINESS WIRE)--Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab.

January 5, 2010 - Pfizer and Strides Arcolab to Collaborate on Generic Products

(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and

January 4, 2010 - Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, PharmaTherapeutics Research & Development, at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010 at 8:30 a.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “28th Annual J.P. Morgan

January 4, 2010 - Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Jeff Kindler, Chairman & CEO, at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Wednesday, January 6, 2010 at 8:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs Healthcare CEOs Unscripted: A View from the Top

January 4, 2010 - European Commission Approves New Intravenous Formulation Of Pfizer’s Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission has approved Revatio® (sildenafil) solution for injection for patients who are currently prescribed oral Revatio and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. Revatio is the only phosphodiesterase 5 (PDE5) inhibitor with both oral and I.V. formulations approved in the European Union for the

December 30, 2009 - Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine. As a result, the review will continue beyond the prescription drug user fee (PDUFA) action date of December 30, 2009.

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.